MARKET ACCESS OF ORPHAN DRUGS IN EUROPE (MORE)
MORE is run by a dynamic team of researchers, who wish to inform the public on the developments regarding orphan drugs, their reimbursement and budget impact. Their aim is to support health systems in providing equal and sustainable access to these life-saving medicines.
OUR MISSION
Inform
about new information the emerges around the funding and availability of orphan drugs
Discuss
how we believe that these recent developments will impact current practice
Share
our own research findings and adding to the public knowledge around market access of orphan drugs
An orphan drug is intended for the diagnosis, prevention or treatment of a life-threatening or chronically and seriously debilitating condition affecting less than 5 in 10,000 EU people. An orphan drug that – without incentives – would likely generate insufficient benefit for the affected people and for the drug manufacturer to justify the investment.
European Medicines Agency
Rare disease facts
a rare disease affects
<5 in 10,000
citizens
> 300 million
patients worldwide
less than 40%
of rare disease patients has a normal lifespan
Contact us at
MORE.kuleuven@gmail.com
O&N II Herestraat 49 bus 521
3000 LEUVEN
MORE 